Figure 1 (Arexvy Spl Graphic 01)
Arexvy Kit
Product Images NDC 58160-894
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Arexvy (NDC 58160-894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Glaxosmithkline Biologicals Sa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Arexvy Spl Graphic 02)
This text appears to be a label or specification for a biomedical product. It indicates that the product is in a lyophilized (freeze-dried) form and contains an antigen component in a powdered form. Additional information about the specific product or its intended use is not available.*
Figure 3 (Arexvy Spl Graphic 03)
Figure 4 (Arexvy Spl Graphic 04)
Arexvy 10 Dose Carton (Arexvy Spl Graphic 05)
This is a description of a respiratory syncytial virus vaccine called AREXVY. The package includes 10 vials containing adjuvant suspension component and 10 vials of lyophilized antigen component that need to be combined before use. The reconstituted vaccine has 10 doses, and each dose is 0.5 mL of AREXVY. This vaccine is available only through prescription.*
Arexvy Antigen Vial Label (Arexvy Spl Graphic 06)
Arexvy Adjuvant Vial Label (Arexvy Spl Graphic 07)
This is a medication packaging from GlaxoSmithKline Biologicals. The package contains an adjuvant suspension component and is not intended to be used alone. It also includes NDC and manufacturing details. However, it is not possible to determine the complete details of this medication from this text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
